Dr-Falk-Pharma on Bioeconhttps://en.bioecon.ru/companies/dr-falk-pharma/Recent content in Dr-Falk-Pharma on BioeconHugoen-USTue, 07 Jul 2026 15:55:52 +0700Enzymatic therapy for celiachttps://en.bioecon.ru/technology/enzymatic-therapy-celiac/Tue, 07 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/enzymatic-therapy-celiac/Engineered enzymes and enzyme-target inhibitors are moving toward pharmaceutical protection from gluten exposure in celiac disease — a Barcelona-designed gastric enzyme validated in mouse models, a transglutaminase-2 inhibitor showing histologic protection in human trials, and a $35M Takeda-funded oral enzyme program whose later trial stage reportedly worsened mucosal damage.